针对复发性和耐药性侵袭性淋巴瘤患者的CAR T细胞疗法:来自单一放射治疗中心的现实经验
J T Jutzi1, J Wampfler1, C Ionescu2
1Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Hematological oncology
|August 31, 2025
概括
放射治疗可以改善CAR T细胞治疗后局部复发的侵袭性淋巴瘤患者的治疗结果. 这些实验数据支持进一步的临床试验,以提高CAR T细胞的疗效.
科学领域:
- 癌症学
- 免疫疗法
- 辐射瘤学
背景情况:
- 卡尔T细胞疗法彻底改变了淋巴瘤的治疗方法.
- 局部复发仍然是CAR T细胞治疗结果的一个挑战.
- 在CAR T细胞治疗后,放射治疗对治疗复发性疾病的作用尚不清楚.
研究的目的:
- 评估放射治疗在 CAR T 细胞治疗后出现局部复发的侵袭性淋巴瘤患者的疗效.
- 用放射治疗治疗局部复发的结果与没有复发的结果进行比较.
- 为优化与放射治疗相结合的CAR-T细胞治疗提供未来临床试验设计的信息.
主要方法:
- 一个现实世界队伍的回顾性分析.
- 在2019年至2022年12月期间使用CAR T细胞治疗的90名具有攻击性淋巴瘤的患者.
- 用放射治疗治疗局部复发的患者与没有复发的患者的结局比较.
主要成果:
- 用放射治疗治疗局部复发的结果与没有复发的患者相似.
- 实际数据表明,在这种特定的临床场景中,放射治疗可能有好处.
- 这项研究提供了将放射治疗纳入CAR T细胞治疗方案的初步证据.
结论:
- 在侵袭性淋巴瘤中使用CAR T细胞治疗后,放射治疗可能是治疗局部复发的可行选择.
- 需要进一步的前性临床试验来证实这些发现并优化治疗策略.
- 结合放射治疗和CAR T细胞治疗有望提高整体治疗效果.
相关概念视频
01:27Tumor Immunotherapy
659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K